Doxorubicin hydrochloride

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

No data

Clinical

Clinical Trials

3100 clinical trials

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Breast neoplasms	D001943	EFO_0003869	C50	107	439	208	19	91	796
Lymphoma	D008223	—	C85.9	100	325	123	16	35	536
Large b-cell lymphoma diffuse	D016403	—	C83.3	55	168	56	4	11	257
Sarcoma	D012509	—	—	70	131	48	5	23	248
Ovarian neoplasms	D010051	EFO_0003893	C56	75	111	72	1	16	241
Neoplasms	D009369	—	C80	108	79	16	1	8	184
Non-hodgkin lymphoma	D008228	—	C85.9	43	102	41	6	11	178
B-cell lymphoma	D016393	—	—	52	99	28	5	7	159
Carcinoma	D002277	—	C80.0	34	75	33	5	26	156
Liver neoplasms	D008113	EFO_1001513	C22.0	25	62	42	8	34	152

Show 41 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Triple negative breast neoplasms	D064726	—	—	25	99	21	—	9	141
Fallopian tube neoplasms	D005185	—	—	32	34	28	—	1	81
Recurrence	D012008	—	—	20	32	9	—	6	58
Stomach neoplasms	D013274	EFO_0003897	C16	10	34	11	—	9	58
Neuroblastoma	D009447	EFO_0000621	—	11	22	16	—	3	52
Osteosarcoma	D012516	—	—	13	24	11	—	8	49
Neoplasm metastasis	D009362	EFO_0009708	—	18	27	6	—	4	48
Endometrial neoplasms	D016889	EFO_0004230	—	6	20	20	—	—	44
Adenocarcinoma	D000230	—	—	9	25	9	—	3	41
Peritoneal neoplasms	D010534	—	—	12	16	8	—	6	38

Show 143 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Invasive hydatidiform mole	D002820	—	D39.2	2	13	—	—	—	15
Non-small-cell lung carcinoma	D002289	—	—	5	11	—	—	—	13
Plasmablastic lymphoma	D000069293	—	C83.3	7	6	—	—	—	11
Glioblastoma	D005909	EFO_0000515	—	4	7	—	—	—	10
Cholangiocarcinoma	D018281	—	C22.1	4	6	—	—	2	10
Hypersensitivity	D006967	EFO_0003785	T78.40	4	5	—	—	4	10
Adult t-cell leukemia-lymphoma	D015459	—	C91.5	4	6	—	—	—	9
Syndrome	D013577	—	—	3	6	—	—	—	9
Aids-related lymphoma	D016483	EFO_1001365	—	4	6	—	—	—	9
Urologic neoplasms	D014571	—	C64-C68	4	6	—	—	—	8

Show 145 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Myelodysplastic-myeloproliferative diseases	D054437	—	—	4	—	—	—	—	4
Appendiceal neoplasms	D001063	EFO_0003880	C18.1	2	—	—	—	2	4
Cystadenocarcinoma	D003536	—	—	3	—	—	—	—	3
Skin neoplasms	D012878	EFO_0004198	C44	1	—	—	—	1	2
Sezary syndrome	D012751	—	C84.1	1	—	—	—	1	2
Pleural effusion	D010996	—	J90	1	—	—	—	1	2
Pleural neoplasms	D010997	—	—	1	—	—	—	1	2
Brenner tumor	D001948	—	—	2	—	—	—	—	2
Castration-resistant prostatic neoplasms	D064129	—	—	1	—	—	—	—	1
Primary myelofibrosis	D055728	—	D47.4	1	—	—	—	—	1

Show 17 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Cardiovascular diseases	D002318	EFO_0000319	I98	—	—	—	—	4	4
Fatigue	D005221	—	R53.83	—	—	—	—	2	2
Alopecia	D000505	—	L64	—	—	—	—	2	2
Pseudomyxoma peritonei	D011553	EFO_0007456	—	—	—	—	—	2	2
Inflammation	D007249	MP_0001845	—	—	—	—	—	2	2
Taste disorders	D013651	—	—	—	—	—	—	1	1
Dysgeusia	D004408	—	R43.2	—	—	—	—	1	1
Ageusia	D000370	EFO_1001758	—	—	—	—	—	1	1
Biliary tract neoplasms	D001661	—	C24.9	—	—	—	—	1	1
Ataxia	D001259	—	R27.0	—	—	—	—	1	1